top of page
  • Pauline Lavigne

Understanding and Interpreting the Results of Mineralocorticoid Receptor Antagonists Trials

Friday, December 4th: 4:00 – 6:00 pm

Understanding and Interpreting the Results of Mineralocorticoid Receptor Antagonists (MRA) Trials in Diabetic Kidney Disease (DKD)

Diabetic kidney disease (DKD) is a major health problem worldwide, increasing the risks for heart disease, hypertension, kidney failure and death. Current treatment focuses on aldosterone inhibition, but the available steroidal treatments are associated with undesirable side effects. There is a critical need for new treatments to prevent the development and slow the progression of DKD. Early results from FIDELIO suggest that the non-steroidal aldosterone inhibitor, finerenone, may be the life-saving, silver bullet we have all been waiting for.

This session is chaired by Dr. Rajiv Agarwal an international leader in clinical and translational research in nephrology from the Indiana University School of Medicine at Indianapolis, who was a key investigator on the FIDELIO trial. Co-chairing this session is Dr. Meg Jardine, of UNSW Sydney. Prof. Jardine focuses on using innovative trial designs to improve outcomes, and has acted as the scientific lead on trials such as RESOLVE, BEAT-Calci, and CREDENCE.

Early results of the FIDELIO trial will be presented at the American Society of Nephrology’s Kidney Week 2020 on October 23, 2020. Check out Abstract FR-OR51 (Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes”) before the CVCT and get your questions ready for the esteemed panel speaking at this session.

This session will provide an in depth look at the results of FIDELIO-DKD in presentations by Dr. Agarwal (main renal outcomes), Prof. Stefan Anker (Berlin, GER) (cardiovascular outcomes), and Dr. Gerasimos Filippatos (Athens, GRE) (safety results). But tune in for so much more insight than you can expect from traditional data presentations. Prof. Peter Rossing (Copenhagen, DEN) will discuss what target population you should apply the FIDELIO-DKD results to in clinical practice. Additional speakers include Katherine Tuttle (Seattle, USA), and David DeMets (Madison, USA), who will be joined by an extensive multi-stakeholder expert panel to answer questions and stimulate debate.

Don’t forget to stay tuned after the Keynote lecture for the session at 7 pm EST, for more discussion and insight on the FIDELIO trial including a talk from the trial’s principal investigator, Dr. George Bakris (Chicago, USA).

Making CV Precision Medicine Become a Reality

Thursday, December 3rd: 7:30 – 9:30 pm Advances in disease stratification tools, such as molecular and imaging technologies, will help to identify more specific patient populations. This will help to


bottom of page